Molecular Psychiatry

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Retrieved on: 
Monday, March 18, 2024
Survival, JCO, Caregiver, Therapy, Palliative care, Patient, Ethics, Journal, Mouse, Research, Hebrew University of Jerusalem, Anxiety, MD, Nature, Quality of life, Adjustment disorder, World Health Organization, Adjustment, ASCO, Molecular Psychiatry, WHO, Paper, FDA, PBM

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:PBM) ("Psyence Biomed" or the "Company") today issued a statement welcoming the results of a recent study finding evidence that nature-derived psilocybin may be demonstrably more therapeutic than synthetic psilocybin.

Key Points: 
  • The study presents evidence that nature (mushroom)-derived psilocybin delivers a “more potent and prolonged effect” on “neuroplasticity” than its synthetic analog.
  • “Neuroplasticity” is increasingly recognized as the gold standard by which the therapeutic efficacy of psychedelic pharmaceutical medicines can be measured.
  • The Psyence Biomed study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.
  • Neither Psyence Biomedical nor any of its investors or affiliates funded or in any way sponsored the Hebrew University study.

Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory for Treatment of Alzheimer’s Disease

Retrieved on: 
Thursday, August 18, 2022
Oncology, Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Antibody, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disorder, Mouse, CEO, CNS, Science, Neuron, Clinical trial, Autophagy, Brain, Toxicity, Inc., Amyotrophic lateral sclerosis, SHINE, Research, Environment, Therapy, Tumor microenvironment, Central nervous system, Neurodegeneration, Manuscript, Stem cell, Neuroprotection, Neurogenesis, Homeostasis, AD, MEK, Melanoma, ALS, Food, Adult, Disease, Pharmaceutical industry, Molecular Psychiatry

The article presents findings from Genuvs preclinical experiments treating a mouse model of Alzheimers with SNR1611, a commercially available MEK 1/2 inhibitor.

Key Points: 
  • The article presents findings from Genuvs preclinical experiments treating a mouse model of Alzheimers with SNR1611, a commercially available MEK 1/2 inhibitor.
  • All research relevant to the publication was conducted in Genuvs laboratories or under Genuvs supervision.
  • The new publication in Molecular Psychiatry comes just weeks after an investigation in the journal Science uncovered evidence of potential data fabrication in a paper on Alzheimers disease published in 2006.
  • The publication has intensified interest in alternative approaches to treating Alzheimers disease, including Genuvs novel neuroprotection/neurogenesis hypothesis.

Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress

Retrieved on: 
Thursday, May 12, 2022
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Dementia, Lewy body, ID, R, Private Securities Litigation Reform Act, Research, U.S. Securities and Exchange Commission, Connective tissue disease, Annual report, Nasdaq, Molecular Psychiatry, Biology, AbbVie, Patient, Memory, Form 10-K, Lists of diseases, DPN, Even and odd functions, Investor, Allergan, COVID-19, Inc., Trial of the century, Fibromyalgia, Government budget balance, Brain, APTX, Research and development, Central nervous system, Safety, NMDA, Attention, Security (finance), Administration, Twitter, Fatigue, Post-traumatic stress disorder, Pharmaceutical industry, Surveying, Medical imaging, Mineral wool, Medical device, PTSD

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2022 and highlighted recent progress across the companys pipeline of novel, clinical-stage, NMDA receptor modulators.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2022 and highlighted recent progress across the companys pipeline of novel, clinical-stage, NMDA receptor modulators.
  • Readout of Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022.
  • Enrollment in Aptinyxs Phase 2b study of NYX-295 in fibromyalgia was completed in late February 2022.
  • ET to review its financial results and highlights for the first quarter of 2022 and subsequent period.

Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783

Retrieved on: 
Wednesday, April 20, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Inc., Annual report, Cognition, Fibromyalgia, Lewy body, SSRI, Fear, Government budget balance, PTSD, MPFC, Central and East European Center for Cognitive Science, Lists of disasters, U.S. Securities and Exchange Commission, Neuron, Post-traumatic stress disorder, Korea, Food, Human, Suicide, Lists of diseases, Center, Trauma, Brain, Central nervous system, Dementia, Private Securities Litigation Reform Act, Molecular Psychiatry, Regulation of tobacco by the U.S. Food and Drug Administration, Connective tissue disease, Responsibility, Patient, South Korea, Department, Form 10-K, Substance abuse, Assault, Prefrontal cortex, APTX, Yale School of Medicine, Trial of the century, Nasdaq, Arousal, NMDA, Sociality, NMDAR2B, Abuse, Mouse, Fast Track, Risk, Addiction, Institute, Basic research, Research, Pharmaceutical industry, Antibiotics, Meat

The publication, entitled "Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear," details the ability of NYX-783 to reduce fear-based behaviors in animal models of PTSD by measuring enhanced fear extinction and reduced spontaneous recovery (i.e., return) of fear.

Key Points: 
  • The publication, entitled "Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear," details the ability of NYX-783 to reduce fear-based behaviors in animal models of PTSD by measuring enhanced fear extinction and reduced spontaneous recovery (i.e., return) of fear.
  • These data suggest NYX-783 can inhibit the spontaneous recovery of learned fear even after exposure to an additional significant stressor.
  • The inhibition of spontaneous recovery of learned fear by NYX-783 results from increased NMDAR2B-mediated activity of neurons in the infralimbic medial prefrontal cortex.
  • These results elucidate the cellular targets of NYX-783 and the molecular mechanisms underlying the inhibition of spontaneous recovery.

CHOP Researchers Use Deep Learning to Find Genetic Causes of Mental Health Disorders in Frequently Understudied African American Population

Retrieved on: 
Tuesday, February 1, 2022
Online, Anxiety, ADHD, Disorder, Patient, Health, Genomics, Center, ODD, Philadelphia, Deep learning, Institution, Children's Hospital, Oppositional defiant disorder, CHOP, Children's Hospital of Philadelphia, Lists of diseases, Research, Whole genome sequencing, Intellectual, Autism, Disease, Hospital, Genome, Translational Genomics Research Institute, Doctor of Philosophy, Depression, Molecular Psychiatry, Algorithm, Center for Applied Genomics, Mental disorder, Protein, Machine learning, Medicine, Pharmaceutical industry, Medical device, Child, MD

A new study from researchers at Children's Hospital of Philadelphia (CHOP) shows that a deep learning model has promising accuracy when helping to diagnose a variety of common mental health disorders in African American patients.

Key Points: 
  • A new study from researchers at Children's Hospital of Philadelphia (CHOP) shows that a deep learning model has promising accuracy when helping to diagnose a variety of common mental health disorders in African American patients.
  • Properly diagnosing mental disorders can be challenging, especially for young toddlers who are unable to complete questionnaires or rating scales.
  • Past genomic research has found several genomic signals for a variety of mental disorders, with some serving as potential therapeutic drug targets.
  • Liu et al, "Application of Deep Learning Algorithm on Whole Genome Sequencing Data Uncovers Structural Variants Associated with Multiple Mental Disorders in African American Patients."

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

Retrieved on: 
Monday, October 25, 2021
Science, Depression, Post-traumatic stress disorder, Research, Medicinal chemistry, National academy, MDMA, Yale University, Journal of Medicinal Chemistry, Patient, FDA, U.S. Department of Defense Strategy for Operating in Cyberspace, National Center for Telehealth & Technology, Translational research, Psilocybin, PTSD, Lists of diseases, Ketamine, Leadership, Brain, Company, Mental health, National Academy of Medicine, Translational neuroscience, Awareness, Biological Psychiatry (journal), Molecular Psychiatry, Schizophrenia, Therapy, Publication, Yale New Haven Hospital, Yale Center for Environmental Law & Policy, NASEM, Doctor of Philosophy, Department, U.S. Department of Veterans Affairs, Office of Inspector General, NIAAA, Frontiers, Journal, Pharmaceutical industry

Delix's Scientific and Strategic Advisory Board is comprised of leaders with decades of research and commercial experience to help Delix advance its platform of novel non-hallucinogenic psychedelic-inspired analogs intoorally-bioavailable, take-home therapies.

Key Points: 
  • Delix's Scientific and Strategic Advisory Board is comprised of leaders with decades of research and commercial experience to help Delix advance its platform of novel non-hallucinogenic psychedelic-inspired analogs intoorally-bioavailable, take-home therapies.
  • Delix's scientific approach for developing scalable treatments for brain disorders was recently featured in the scientific journal Frontiers in Psychiatry .
  • Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogensnovel neuroplasticity-promoting therapeuticsto better treat mental health disorders at scale.
  • Delix is rapidly advancing these compounds through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs.